Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2)
Biological Psychiatry, 43(7), 511519
Records, Not Rumors
Its core pathological feature is excessive accumulation of adipose tissue, accompanied by abnormal proliferation, differentiation, and metabolic dysfunction of adipocytes, which in turn induce a series of complications including insulin resistance, nonalcoholic fatty liver disease, and cardiovascular diseases
Strategy 1: Reconstitute only what you need
PMC6073405 BPC-157 angiogenic signaling VEGFR2AkteNOS activation, nitric oxide bioavailability, FAK-paxillin cell-anchoring cascade, anti-cytokine modulation: PMC8275860 TB-4 / TB-500 G-actin sequestration and threshold-saturation mechanism actin-monomer binding, cytoskeletal mobilization for cell migration, mass-action pharmacodynamics requiring bolus dosing: PubMed 12581423 TB-4 Ac-SDKP anti-fibrotic fragment N-terminal tetrapeptide (fragment 14) released by meprin- and POP processing